June 16, 2006, Newsletter Issue #20: The Bextra debate
Tip of the Week
More than 10 million people were using a COX-2 anti-inflammatory drug on Sept. 30, 2004, when Merck announced Vioxx's withdrawal, followed by a suspension of sales of Bextra by Pfizer. In 2003, Vioxx, Celebrex, and Bextra reaped more than $6 billion in sales, driven by $400 million in advertising targeting doctors and consumers. These sales were driven by claims that COX-2 anti-inflammatory drugs were safer than older NSAIDs such as Motrin, Voltaren, and Naprosyn; claims that have still not convinced many experts, especially in light of recent new studies.
About LifeTips
Now one of the top on-line publishers in the world, LifeTips offers tips to millions of monthly visitors. Our mission mission is to make your life smarter, better, faster and wiser. Expert writers earn dough for what they know. And exclusive sponsors in each niche topic help us make-it-all happen.
